PIKfyve inhibitors

A compound selected from:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is selected from H and C1-6 alkyl optionally substituted with ORa2;
• R2 is C1-6 alkyl optionally substituted with ORa2;
• or
• R1 and R2 together form a 4-7 membered heterocycloalkyl, which is optionally substituted with 1, 2, or 3 substituents independently selected R8;
• each R8 is selected from C1-6 alkyl and ORa2;
• Ra2 is selected from H and C1-6 alkyl;
• R3 is selected from H, C1-6 alkyl, and C1-6 haloalkyl;
• R4 is selected from H, C1-6 alkyl, and C1-6 haloalkyl;
• each R7 is selected from halo, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1S(O)2Rb1, S(O)2Rb1, and S(O)2NRc1Rd1;
• Ra1, Rc1, and Rd1 are each independently selected from H, C1-6 alkyl, and C1-4 haloalkyl;
• each Rb1 is independently selected from C1-6 alkyl and C1-4 haloalkyl;
• RA is selected from H, C1-6 alkyl, and C1-6 haloalkyl;
• RB is selected from H, C1-6 alkyl, and C1-6 haloalkyl;
• RC is selected from C6-10 aryl, 5-membered heteroaryl, and 7-10 membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, ORa3, NRc3Rd3 NRc3C(O)Rb3, and NRc3S(O)2Rb3;
• Ra3, Rc3, and Rd3 are each independently selected from H, C1-6 alkyl, and C1-4 haloalkyl;
• and
• each Rb3 is independently selected from C1-6 alkyl and C1-4 haloalkyl.